Versant Capital Management
ORKA icon

Versant Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Versant Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.16K Hold
98
– – ﹤0.01% 2323
2026
Q2 		$9.33K Hold
98
– – ﹤0.01% 2253
2026
Q1 		$4.81K Buy
+98
New +$3.41K ﹤0.01% 2391

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Remedium Capital Partners
Remedium Capital Partners Fort Lauderdale, Florida $274M AUM 288.41% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Versant Capital Management's ORKA Position: Q3 2026 in Review

Versant Capital Management held its Oruka Therapeutics (ORKA) position steady in Q3 2026 at 98 shares worth $8.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Versant Capital Management first reported a position in ORKA in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.33K in Q2 2026. 175 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Versant Capital Management held 98 shares of Oruka Therapeutics worth $8.16K as of Q3 2026.
  • Versant Capital Management left its Oruka Therapeutics share count unchanged in Q3 2026.
  • Oruka Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2323 holding.
  • Versant Capital Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Versant Capital Management's Oruka Therapeutics position peaked at $9.33K in Q2 2026.
  • 175 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.